Waverly Advisors LLC Sells 36,956 Shares of Novo Nordisk A/S $NVO

Key Points

• Waverly Advisors cut its Novo Nordisk stake by 79.5% in the second quarter, selling 36,956 shares and retaining 9,554 shares valued at approximately $458,000.
• Analyst sentiment remains cautious: Novo Nordisk has a consensus “Hold” rating and a $64.94 average price target, with 14 Holds, three Buys and one Sell.
• NVO shares opened at $41.70, near the lower end of their 52-week range, as investors weigh pipeline initiatives—including an Anthropic AI partnership and upcoming obesity-drug data—against competitive pressure from Eli Lilly and limited near-term financial visibility.

Waverly Advisors LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 79.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,554 shares of the company's stock after selling 36,956 shares during the quarter. Waverly Advisors LLC's holdings in Novo Nordisk A/S were worth $458,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of NVO. Nykredit A S bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at $289,000. Parkside Financial Bank & Trust boosted its holdings in Novo Nordisk A/S by 13.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 2,436 shares of the company's stock valued at $117,000 after purchasing an additional 283 shares during the period. Range Advisory LLC purchased a new position in Novo Nordisk A/S during the second quarter worth about $213,000. Amundi purchased a new position in shares of Novo Nordisk A/S during the second quarter worth about $288,000. Finally, HighTower Advisors LLC grew its stake in Novo Nordisk A/S by 71.6% in the 2nd quarter. HighTower Advisors LLC now owns 403,262 shares of the company's stock worth $19,332,000 after buying an additional 168,196 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on NVO. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating in a research report on Thursday, August 27th. HSBC reissued a "hold" rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Citigroup reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Berenberg Bank set a $47.00 price objective on Novo Nordisk A/S in a report on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus target price of $64.94.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk is partnering with Anthropic to use Claude and other AI models in drug discovery, research and development, and software engineering. The companies say the collaboration could improve scientific reasoning and accelerate the development of new medicines, potentially making Novo’s R&D process more efficient. Financial terms and specific productivity targets were not disclosed. Novo and Anthropic will collaborate to advance drug discovery
• Positive Sentiment: Novo plans to present 44 abstracts at the European Association for the Study of Diabetes conference, including new data on the Wegovy pill, Wegovy 7.2 mg, Ozempic 2.0 mg, CagriSema and next-generation amylin treatments. The updates could provide investors with evidence of pipeline progress and broader cardiometabolic applications. Novo to share real-world and clinical data at EASD 2026
• Neutral Sentiment: The broader healthcare sector also edged lower, providing an unfavorable market backdrop for pharmaceutical stocks and contributing to the pressure on NVO. Sector Update: Healthcare Stocks Edge Lower Late Afternoon
• Negative Sentiment: Investors remain skeptical that the Anthropic agreement will produce near-term financial benefits because neither company provided cost savings, revenue targets or a timetable for measurable results. The announcement therefore appears more strategic than immediately earnings-accretive. Novo Drops as Claude Enters Drug Development
• Negative Sentiment: The recent rebrand to “Novo” and management’s push for a more consumer-focused culture highlight pressure from Eli Lilly in the obesity-drug market. Investors appear to want evidence of stronger execution, market-share recovery and a convincing growth strategy rather than branding changes alone. Novo CEO urges staff to embrace a more customer-focused culture

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $41.70 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company has a fifty day moving average of $47.08 and a 200-day moving average of $43.77. The stock has a market capitalization of $186.18 billion, a price-to-earnings ratio of 10.19, a price-to-earnings-growth ratio of 1.40 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. Equities research analysts expect that Novo Nordisk A/S will post 3.53 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S's dividend payout ratio (DPR) is 20.05%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.